What is the contribution of IgE to nasal polyposis?
| 171. | Bachert, C.+, Maurer, M., Palomares, O., and Busse, W. W.: What is the contribution of IgE to nasal polyposis? J. Allergy Clin. Immunol. 2021: 147; 1997-2008. IF: 14.29 |
r.171
IgE
Response of omalizumab in normocomplementemic urticarial vasculitis
| 386. | Chen, Y.-D., Krause, K., Tu, P., Zhao, Z.+, and Maurer, M.+: Response of omalizumab in normocomplementemic urticarial vasculitis. J. Allergy Clin. Immunol. Pract. 2020: 8; 2114-2117. IF: 8.86 |
o.386
Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients
| 383. | Altrichter, S., Schumacher, P., Alraboni, O., Wang, Y., Hiragun, M., Hide, M., and Maurer, M.+: Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients. Clin. Transl. Allergy 2020: 10; 18. IF: 5.87 |
o.383
The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria
| 92. | Chang, T. S., Chen, C., Lin, C.-J., Metz, M., Church, M. K., and Maurer, M.: The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J. Allergy Clin. Immunol. 2015: 135; 337-342. IF: 12.48 |
r.092
Mast cells: makers and breakers of allergic inflammation
| 31. | Hakim-Rad, K., Metz, M., and Maurer, M.: Mast Cells: Makers and Breakers of allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 2009: 9; 427-430. IF: 3.15 |
Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence
| 129. | Maurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., and Magerl, M.: Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J. Allergy Clin. Immunol. 2018: 141; 638-649. IF: 14.11 |
r.129
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA²LEN project
| 13. | Bousquet, J., Anto, J. M., Bachert, C., Bousquet, P. J., Colombo, P., Crameri, R., Daeron, M., Fokkens, W., Leynaert, B., Lahoz, C., Maurer, M., Passalacqua, G., Valenta, R., van Hage, M., and van Ree, R.: Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA²LEN project. Allergy 2006: 61; 671-680. IF 5.33 |
r.013
IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J
| 325 | Schmetzer, O.+, Lakin, E., Topal, F. A., Preusse, P., Freier, D., Church, M. K., and Maurer, M.: IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J. Allergy Clin. Immunol. 2018: 142; 876-882. IF: 14.11) |
On the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria
| 338 | Lakin, E., Church, M. K., Maurer, M.+, and Schmetzer, O.: On the lipophilic nature of the autoreactive IgE in chronic spontaneous urticaria. Theranostics 2019: 9; 829-836. IF: TBD (IF 2018: 8.06) |